Genetic liability to asthma and risk of cardiovascular diseases: A Mendelian randomization study

Heng Chen¹, Wei Chen²† and Liangrong Zheng¹*

¹Department of Cardiology, The First Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou, China, ²Department of Respiratory and Critical Care Medicine, Ruian People’s Hospital, Wenzhou, China

Background and Aims: Epidemiological studies have suggested positive associations between asthma and the risk of cardiovascular diseases (CVDs). However, causality remains inconclusive. We aim to explore the causal associations between asthma and CVDs risk using the Mendelian Randomization (MR) approach.

Methods: We obtained summary-level data for eight CVDs [including atrial fibrillation (AF), coronary artery disease (CAD), heart failure (HF), stroke, ischemic stroke, large artery stroke, small vessel stroke, and cardioembolic stroke] from several large genome-wide association studies (GWASs) and the FinnGen consortium. Nine lead single-nucleotide polymorphisms associated with asthma ($p < 5 \times 10^{-8}$) were identified from the GWAS conducted by the Trans-National Asthma Genetic Consortium. MR analyses were performed using the inverse variance weighted method, supplemented by the weighted median and MR-Egger methods.

Results: Inverse variance weighted method showed suggestive effects of genetically determined asthma on AF (odds ratio (OR), 1.08; 95% confidence interval (CI), 1.02, 1.14; $p = 0.009$) and HF (OR, 1.05; 95% CI, 1.01, 1.09; $p = 0.029$). We found no causal associations between asthma and other CVDs. No horizontal pleiotropy was observed.

Conclusion: This MR study provides genetic evidence suggesting a causal association between asthma and the risk of AF and HF, although not at the level of significance after multiple testing correction. Programs aimed at treating asthma among asthmatics might help prevent the adverse health effects inflicted by CVDs.

KEYWORDS
Mendelian randomization, causal association, asthma, atrial fibrillation, heart failure, coronary artery disease, stroke
Introduction

With the aging of the global population, cardiovascular diseases (CVDs) have become major public health problems and represent the leading causes of morbidity and mortality worldwide (Lennon et al., 2018). Primary prevention strategies for CVDs have been extensively studied for decades.

Asthma is a common respiratory disorder characterized by reversible airflow obstruction (Mooran et al., 2012). Epidemiological studies have reported associations between asthma and CVDs. A cohort study including 54,567 individuals showed that patients with asthma experienced a higher risk of atrial fibrillation (AF) (adjusted hazard ratio (HR), 1.38, 95% CI, 1.18, 1.61) over a 15.4-years follow-up (Cepelis et al., 2018). A meta-analysis demonstrated that asthma was associated with increased risks of coronary artery disease (CAD) in both prospective studies (HR, 1.34, 95% CI, 1.09, 1.64) and retrospective studies (odds ratio (OR), 1.29, 95% CI, 1.13, 1.46) (Wang et al., 2017). Besides, asthma has been associated with a higher risk of heart failure (HF) as well as stroke (Iribarren et al., 2012; Wen et al., 2016). However, causality remains unknown. It is uncertain whether previously observed associations were biased by residual confounders and/or reverse causation (Smith and Ebrahim, 2003).

Mendelian Randomization (MR) is an extensively used approach to investigated causal relationships between exposures and outcomes. It takes advantage of naturally randomized genetic variants as instrumental variables (IVs), and will not be easily affected by confounding factors or reverse causation (Lawlor et al., 2008). A very recent MR study conducted by Zhou et al. explored a similar topic (Zhou et al., 2021). In the present study, we independently used different IVs and different data sources for CAD, MI and HF. Importantly, for the first time we investigated the potential causal association between asthma and AF.

Methods

Study design

We performed a two-sample MR study to investigate the causal associations between asthma and the risk of CVDs. The MR approach was based on three key assumptions. First, IVs should be robustly associated with CVDs; second, there is no association between the SNPs and potential confounders; third, IVs lead to CVDs only through their effects on asthma (Burgess et al., 2015). A checklist of the Strengthening the Reporting of Observational Studies in Epidemiology Using Mendelian Randomization (STROBE-MR) guideline (Krivankova et al., 2021) was provided in Supplementary Table S1.

Detailed information on data sources is presented in Table 1. We included eight CVDs endpoints with cases numbers ranging from 4,373 (large artery stroke) to 60,801 (coronary artery disease). Summary statistics for the associations of the IVs with CVDs were obtained from Coronary Artery Disease Genome-wide Replication and Meta-analysis plus The Coronary Artery Disease Genetics (CARDIoGRAMplusC4D) consortium for CAD (Nikpay et al., 2015), GWAS meta-analysis by Nielsen et al. for AF (Nielsen et al., 2018), Heart Failure Molecular Epidemiology for Therapeutic Targets (HERMES) consortium for HF (Shah et al., 2020), and MEGASTROKE consortium for stroke and stroke subtypes (Malik et al., 2018). We also used summary-level data from FinnGen (FinnGen_Consortium, 2022) for replication purpose. FinnGen is a medical project launched in 2017 that includes 500,000 Finnish participants and aims to combine genomic information with health data so as to improve human well-being through genetic research (FinnGen_Consortium, 2022). Ethics approval and informed consent were provided in these publicly available databases.

Validation of instrumental SNPs

First, we identified 16 single-nucleotide polymorphisms (SNPs) associated with asthma at the genome-wide significance level ($p < 5 \times 10^{-8}$) from a large GWAS meta-analysis conducted by the Trans-National Asthma Genetic Consortium (included up to 19,954 cases and 107,715 controls of European descent) (Demenais et al., 2018)(Table 1). Asthma cases were defined based on clinical diagnosis and/or standardized questionnaires. Approximately 37% of cases were defined as asthma onset at or before 16 years of age and the rest were defined as adult asthma (Demenais et al., 2018). Valid MR estimates depended on no linkage disequilibrium ($r^2 < 0.001$) across selected SNPs; thus, we removed rs11071558 since it was in correlation with other SNPs (based on 1000 genomes project, $r^2 > 0.9$). We also used summary-level data from FinnGen (FinnGen_Consortium, 2022) for replication purpose. FinnGen is a medical project launched in 2017 that includes 500,000 Finnish participants and aims to combine genomic information with health data so as to improve human well-being through genetic research (FinnGen_Consortium, 2022). Ethics approval and informed consent were provided in these publicly available databases.

Validation of instrumental SNPs

First, we identified 16 single-nucleotide polymorphisms (SNPs) associated with asthma at the genome-wide significance level ($p < 5 \times 10^{-8}$) from a large GWAS meta-analysis conducted by the Trans-National Asthma Genetic Consortium (included up to 19,954 cases and 107,715 controls of European descent) (Demenais et al., 2018)(Table 1). Asthma cases were defined based on clinical diagnosis and/or standardized questionnaires. Approximately 37% of cases were defined as asthma onset at or before 16 years of age and the rest were defined as adult asthma (Demenais et al., 2018). Valid MR estimates depended on no linkage disequilibrium ($r^2 < 0.001$) across selected SNPs; thus, we removed rs11071558 since it was in correlation with other SNPs (based on 1000 genomes project, $r^2 > 0.9$). We also used summary-level data from FinnGen (FinnGen_Consortium, 2022) for replication purpose. FinnGen is a medical project launched in 2017 that includes 500,000 Finnish participants and aims to combine genomic information with health data so as to improve human well-being through genetic research (FinnGen_Consortium, 2022). Ethics approval and informed consent were provided in these publicly available databases.

Validation of instrumental SNPs

First, we identified 16 single-nucleotide polymorphisms (SNPs) associated with asthma at the genome-wide significance level ($p < 5 \times 10^{-8}$) from a large GWAS meta-analysis conducted by the Trans-National Asthma Genetic Consortium (included up to 19,954 cases and 107,715 controls of European descent) (Demenais et al., 2018)(Table 1). Asthma cases were defined based on clinical diagnosis and/or standardized questionnaires. Approximately 37% of cases were defined as asthma onset at or before 16 years of age and the rest were defined as adult asthma (Demenais et al., 2018). Valid MR estimates depended on no linkage disequilibrium ($r^2 < 0.001$) across selected SNPs; thus, we removed rs11071558 since it was in correlation with other SNPs (based on 1000 genomes project, $r^2 > 0.9$). We also used summary-level data from FinnGen (FinnGen_Consortium, 2022) for replication purpose. FinnGen is a medical project launched in 2017 that includes 500,000 Finnish participants and aims to combine genomic information with health data so as to improve human well-being through genetic research (FinnGen_Consortium, 2022). Ethics approval and informed consent were provided in these publicly available databases.
associated SNPs were leveraged as IVs (Supplementary Table S3). Furthermore, F-statistics were calculated to detect the presence of weak IVs bias with the following formula: $F = R^2 \times (N-2)/(1-R^2)$ (Burgess and Thompson, 2011), where $R^2$ indicates the proportion of variance in asthma explained by each selected SNP (calculated with the method described previously (Shim et al., 2015)) and $N$ represents the sample size. No proxy-SNP was necessary since all the SNPs that we used were available in the CVDs datasets.

**Statistical analysis**

Wald estimator was used to calculate MR estimates. We employed the inverse variance weighted (IVW) (Burgess et al., 2017) approach in the multiplicative random-effects model as the main statistical method to assess the causal associations between genetic liability to asthma and the risk of CVDs. Then, we combined MR estimates for each outcome from different data sources using the fixed-effects meta-analysis method. The IVW method provides the highest statistical power but may be biased if IVs exhibit horizontal pleiotropy (Bowden et al., 2015). Therefore, we performed sensitivity analyses including the weighted median (Bowden et al., 2016) and the MR-Egger regression (Burgess and Thompson, 2017) methods to test the robustness of our results and potential pleiotropy. The weighted median method can provide unbiased causal estimates when more than half of the weight comes from valid SNPs (Bowden et al., 2016). MR-Egger regression method can generate estimates corrected for pleiotropy (Burgess and Thompson, 2017). In addition, a $p$-value $< 0.05$ for the MR-Egger intercept was considered to indicate the presence of pleiotropic bias (Bowden et al., 2015). Furthermore, we calculated the $I^2$ statistics to assess the degree of heterogeneity among the SNPs in the IVW analyses (low, $< 25%$; moderate, $> 50%$; and high, $> 75%$) (Greco M et al., 2015)(Supplementary Table S4). The OR estimate of CVDs and the corresponding confidence intervals (CIs) were scaled per-1-log unit increase in the risk of asthma. A two-sided $p$-value of $< 0.0063$ (0.05/8 outcomes) was considered statistically significant, and associations with $p$-values between 0.0063 and 0.05 were deemed as suggestive associations.

All MR analyses were conducted using the TwoSampleMR package in R Software 4.1.0 (R_Core_Team, 2021).

**Results**

Detailed information on the characteristics of the selected SNPs is provided in Supplementary Table S3. Altogether they explained approximately 5.22% of the phenotypic variability of asthma. All the included SNPs have F-statistics higher than 30, suggesting that they were strong enough to predict asthma in the present study. There is no sample overlap between the data sources for asthma and CVDs.

IVW analyses showed suggestive causal associations between genetically determined asthma and the risk of AF in the GWAS meta-analysis conducted by Nielsen et al. (OR, 1.09; 95% CI, 1.01, 1.14; $p = 0.018$; Figure 1) and HF in HERMES (OR, 1.05; 95% CI, 1.00, 1.11; $p = 0.034$; Figure 1). Both the associations remained directionally consistent in the FinnGen consortia, and the suggestive associations persisted in the meta-analysis combining different data sources (AF: OR, 1.08; 95% CI, 1.02, 1.14; $p = 0.009$; HF: OR, 1.05; 95% CI, 1.01, 1.09; $p = 0.029$; Figure 1). We did not observe a clear pattern of associations

| Phenotype          | Data source                  | Cases | Controls | Population |
|--------------------|------------------------------|-------|----------|------------|
| Asthma             | TAGC                         | 19,954| 107,715  | European   |
| Atrial fibrillation| Nielsen et al               | 60,620| 970,216  | European   |
| Coronary artery disease | CARDIoGRAMplusC4D    | 60,801| 123,504  | 77% European |
| Heart failure      | HERMES                      | 47,309| 930,014  | European   |
| Stroke             | MEGASTROKE                   | 40,585| 406,111  | European   |
| Ischemic stroke    | MEGASTROKE                   | 34,217| 406,111  | European   |
| Large artery stroke| MEGASTROKE                   | 4,373 | 146,392  | European   |
| Small vessel stroke| MEGASTROKE                   | 5,386 | 192,662  | European   |
| Cardioembolic stroke| MEGASTROKE                  | 7,193 | 204,570  | European   |

TAGC, Trans-National Asthma Genetic Consortium; CARDIoGRAMplusC4D, Coronary ARtery Disease Genome-wide Replication and Meta-analysis (CARDIoGRAM) plus The Coronary Artery Disease (C4D) genetics; HERMES, heart failure molecular epidemiology for therapeutic targets.
between genetic liability to asthma and the risk of CAD, stroke, or stroke subtypes (Figure 1).

The associations of asthma with AF and HF were directionally consistent but with noticeably wider CIs in sensitivity analyses based on the weighted median and MR-Egger methods (Supplementary Table S4). The results of no associations between genetically predicted asthma and other CVD outcomes were replicated in both sensitivity analyses (Supplementary Table S4). We found modest heterogeneity in several analyses. For all outcomes considered, there was no evidence of horizontal pleiotropy based on the intercept term in the MR-Egger regression (P_intercept > 0.05) (Supplementary Table S4). Scatter plots of the SNP-exposure and SNP-outcome associations were provided in Supplementary Figures S1–S4.

**Discussion**

This MR study suggests causal associations between genetically determined asthma and the risk of AF and HF. No clear pattern of associations of asthma with the risk of CAD, stroke, or stroke subtypes were found.

Given that asthma and AF shared an underlying inflammatory pathophysiological mechanism (Busse, 1998; Andrade et al., 2014), investigators in the past decade have sought to assess the association between asthma and AF risk using epidemiological approaches. A population-based nested case-control study suggested asthma to be associated with an increased risk of AF (OR 1.2; 95% CI 1.11–1.30) (Chan et al., 2014). In a large multiethnic cohort study (included 17,514 individuals) with 12.9 years of follow-up, the researchers reported that it was patients with persistent asthma, rather than those with intermittent asthma, who experienced a higher risk of atrial fibrillation (hazard ratio (HR), 1.49; 95% CI, 1.03–2.14) compared with non-asthmatics (Tattersall et al., 2020). The association was further strengthened by another prospective population cohort study that revealed a dose-response relationship between levels of asthma control and the risk of AF (Cepelis et al., 2018). In line with these findings, this MR study provides genetic evidence showing that asthma may lead to an increased risk of AF. Medication use for asthma control, such as β2-agonists, is one of the potential explanations for the causal association; the drug has been demonstrated to increase the risk of arrhythmias (Salpeter et al., 2004). Besides, chronic inflammation in the pathogenesis of asthma may cause electrical and structural remodeling of the atria, thereby participating in the onset and continuation of AF (Murdoch and Lloyd, 2010; Hu et al., 2015).

Our result regarding the suggestive causal association between asthma and the risk of HF collaborates with a prospective cohort study which reported that asthma was associated with a 114% increased risk of HF (Iribarren et al., 2012). On the other hand, Sun et al. (Sun et al., 2017) performed prospective analyses among 1118 participants with or without a history of asthma from childhood. They reported that adults with a history of childhood asthma had a greater left ventricular mass

### Table 1

| CVD                          | Data source          | Cases    | SNPs, n | OR (95% CI) | P-value |
|------------------------------|----------------------|----------|---------|-------------|---------|
| Atrial fibrillation          | Nielsen et al.       | 60,620   | 9       | 1.09 (1.01, 1.17) | 0.018   |
| Atrial fibrillation          | FinnGen              | 28,670   | 9       | 1.06 (0.97, 1.16) | 0.227   |
| Meta-analysis                |                      |          |         | 1.08 (1.02, 1.14) | 0.009   |
| Coronary artery disease      | CARDioGRAMplusC4D   | 60,801   | 9       | 0.98 (0.93, 1.04) | 0.593   |
| Coronary artery disease      | FinnGen              | 25,707   | 9       | 1.00 (0.91, 1.1)  | 0.987   |
| Meta-analysis                |                      |          |         | 0.99 (0.94, 1.03) | 0.584   |
| Heart failure                | HERMES               | 47,309   | 9       | 1.06 (1.00, 1.11) | 0.034   |
| Heart failure                | FinnGen              | 30,008   | 9       | 1.03 (0.95, 1.12) | 0.480   |
| Meta-analysis                |                      |          |         | 1.05 (1.01, 1.09) | 0.029   |
| Any stroke                   | MEGASTRKKE           | 40,585   | 9       | 0.99 (0.94, 1.05) | 0.800   |
| Any stroke                   | FinnGen              | 22,701   | 9       | 0.97 (0.91, 1.04) | 0.390   |
| Meta-analysis                |                      |          |         | 0.96 (0.94, 1.03) | 0.480   |
| Ischemic stroke              | MEGASTRKKE           | 34,217   | 9       | 0.97 (0.92, 1.03) | 0.341   |
| Ischemic stroke              | FinnGen              | 12,946   | 9       | 0.99 (0.91, 1.06) | 0.695   |
| Meta-analysis                |                      |          |         | 0.96 (0.94, 1.02) | 0.320   |
| Large artery stroke          | MEGASTRKKE           | 4,373    | 9       | 1.10 (1.00, 1.22) | 0.065   |
| Small vessel stroke          | MEGASTRKKE           | 5,368    | 9       | 0.99 (0.90, 1.10) | 0.853   |
| Cardiovascular stroke        | MEGASTRKKE           | 7,183    | 9       | 1.03 (0.80, 1.19) | 0.645   |

**FIGURE 1**

Associations of genetic liability to asthma with the risk of cardiovascular diseases. SNPs, single-nucleotide polymorphisms; OR, odds ratio; CI, confidence interval; CARDioGRAMplusC4D, Coronary ARtery DIsease Genome-wide Replication and Meta-analysis plus The Coronary Artery Disease Genetics; HERMES, Heart Failure Molecular Epidemiology for Therapeutic Targets.

Chen et al. 10.3389/fgene.2022.879468
index, which was commonly used as a predictor for progression and severity stages of HF (Shah et al., 2017). However, mechanisms for this epidemiological association remain unestablished. Given that AF is one of the well-known risk factors for HF (Carlisle et al., 2019), we recognize that the asthma-AF association may, at least in part, explain the asthma-HF association that we observed.

Data surrounding the association between asthma and CAD is controversial among prospective studies and retrospective studies (Liss et al., 2000; Iribarren et al., 2004; Onufrak et al., 2008; Iribarren et al., 2012). To determine whether asthma leads to a higher risk of CAD, Liu et al. conducted a meta-analysis that included seven studies with 12 cohorts (Liu et al., 2017). The analysis concluded that there was a significant relationship between asthma and CAD risk (HR, 1.42; 95% CI, 1.30–1.57) (Liu et al., 2017). Likewise, epidemiological evidence from another meta-analysis suggested a significant association of asthma with stroke risk (HR, 1.32; 95% CI, 1.13–1.54) (Wen et al., 2016). Our study, on the contrary, does not provide evidence of causal effects of asthma on CAD, stroke, or stroke subtypes, suggesting that associations observed clinically are likely to be biased. Further clinical study on a larger scale is warranted to better elucidate this issue.

A recent MR study on the similar topic reported by Zhou et al. (Zhou et al., 2021) shared some conclusions with us, including the causal association between asthma and HF, and no causal associations for CAD, stroke, and stroke subtypes. Their independent study used different IVs and came to similar results. However, AF was included as an outcome in the present study for the first time. Our analyses further revealed that efforts to treat asthma will probably lead to a reduced risk of AF.

The major strength of this study is the MR method which is less susceptible to potential confounding factors and other biases, thus reinforcing the causal inference. Second, we assessed the potential associations using summary statistics from several large GWASs. The similar results across different data sources assured the reliability of our findings. In addition, our findings were unlikely to be impacted by population structure bias since the analyses were restricted to individuals of European ancestry, except for the analysis for CAD (77% European; Table 1).

There are several limitations worth noting in this study. First, although we have excluded potential pleiotropic SNPs and MR-Egger regression indicated little horizontal pleiotropy, the influence of pleiotropy bias remains a concern in this study. Specifically, psychiatric traits such as major depressive disorder and neuroticism may be confounding factors in the causal associations between asthma and CVDs (Cao et al., 2021; Wu et al., 2021; Zhang et al., 2021, 2022). Besides, the divergent results of sensitivity analyses may indicate a bias of genetic pleiotropy towards asthma-AF and asthma-HF associations that we observed. Second, we are not able to detect potential non-linear associations between asthma severity and the risk of CVDs since this study was based on summary-level data. In addition, the mixed population of CardiogramplusC4D consortium may affect the result of the corresponding analysis. Therefore, caution must be applied here. Another limitation is the limited generalizability of this study given the restriction of subjects largely of European ancestry. It would be of great interest to explore the causal associations on other populations. Future studies are warranted to extend our findings.

**Conclusion**

This MR study revealed suggestive causal associations between asthma and the risk of AF and HF, despite none of the associations achieve a significance value upon multiple testing correction either in the original analysis or the meta-analysis. Interventions to treat asthma might benefit the primary prevention for AF and HF among asthmatics. No causal associations were observed between asthma and the risk of CAD, stroke, or stroke subtypes.

**Data availability statement**

The original contributions presented in the study are included in the article/Supplementary Material, further inquiries can be directed to the corresponding author.

**Author contributions**

Study conception and design: HC and WC; data analyses: HC and WC; draft preparation: HC and WC; supervision of the study: LZ.

**Funding**

This work was supported by the National Natural Science Foundation of China [grant number 81873484]; the Youth Program of the National Natural Science Foundation of China (grant number 82000316); and the Nature Science Foundation of Zhejiang Province (grant number LZ16H020001).

**Acknowledgments**

The authors thank the GWAS meta-analysis of atrial fibrillation (Nielsen et al.), CARDioGRAMplusC4D (Coronary ARtery DIsease Genome-wide Replication and Meta-analysis plus The Coronary Artery Disease Genetics), HERMES (Heart Failure Molecular Epidemiology for Therapeutic Targets) consortium, MEGASTROKE, TAGC (Trans-National Asthma Genetic Consortium) and the FinnGen consortium for providing summary-level data.
Conflict of interest

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Publisher’s note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

Supplementary material

The Supplementary Material for this article can be found online at: https://www.frontiersin.org/articles/10.3389/fgene.2022.879468/full#supplementary-material
R Core Team (2021). R: A language and environment for statistical computing. Vienna, Austria: R Foundation for Statistical Computing. Available at: https://www.R-project.org/.

Salpeter, S. R., Ormiston, T. M., and Salpeter, E. E. (2004). Cardiovascular effects of beta-agonists in patients with asthma and COPD: A meta-analysis. Chest 125 (6), 2309–2321. doi:10.1378/chest.125.6.2309

Shah, A. M., Claggett, B., Loehr, L. R., Chang, P. P., Matsushita, K., Kitzman, D., et al. (2017). Heart failure stages among older adults in the community: The atherosclerotic risk in communities study. Circulation 135 (3), 224–240. doi:10.1161/CIRCULATIONAHA.116.032361

Shah, S., Henry, A., Rosell, C., Lin, H., Svenningsen, G., Fatemifar, G., et al. (2020). Genome-wide association and Mendelian randomisation analysis provide insights into the pathogenesis of heart failure. Nat. Commun. 11 (1), 163. doi:10.1038/s41467-019-13690-5

Shim, H., Chasman, D. I., Smith, J. D., Mora, S., Ridker, P. M., Nickerson, D. A., et al. (2015). A multivariate genome-wide association analysis of 10 LDL subfractions, and their response to statin treatment, in 1868 Caucasians. PLoS One 10 (4), e0120758. doi:10.1371/journal.pone.0120758

Skrivankova, V. W., Richmond, R. C., Woolf, B. A. R., Yarmolinsky, J., Davies, N. M., Swanson, S. A., et al. (2021). Strengthening the reporting of observational studies in epidemiology using mendelian randomization. The STROBE-MR statement. JAMA 326 (16), 1614–1621. doi:10.1001/jama.2021.18236

Smith, G. D., and Ebrahim, S. (2003). Mendelian randomization: Can genetic epidemiology contribute to understanding environmental determinants of disease? Int. J. Epidemiol. 32 (1), 1–22. doi:10.1093/ije/dyg070

Sun, D., Wang, T., Heianza, Y., Lv, J., Han, L., Rabito, F., et al. (2017). A history of asthma from childhood and left ventricular mass in asymptomatic young adults. The Bogalusa heart study. JACC. Heart Fail. 5 (7), 497–504. doi:10.1016/j.jchf.2017.03.009

Tattersall, M. C., Dassie, A. S., McClelland, R. L., Gepner, A. D., Kalscheur, M. M., Field, M. E., et al. (2020). Persistent asthma is associated with increased risk for incident atrial fibrillation in the MESA. Circ. Arrhythm. Electrophysiol. 13 (2), e007685. doi:10.1161/CIRCEP.119.007685

Wang, L., Gao, S., Yu, M., Sheng, Z., and Tan, W. (2017). Association of asthma with coronary heart disease: A meta analysis of 11 trials. PLoS One 12 (6), e0179335. doi:10.1371/journal.pone.0179335

Wen, L. Y., Ni, H., Li, K. S., Yang, H. H., Cheng, J., Wang, X., et al. (2016). Asthma and risk of stroke: A systematic review and meta-analysis. J. Stroke Cerebrovasc. Dis. 25 (3), 497–503. doi:10.1016/j.jstrokecerebrovasdis.2015.11.030

Wu, Y., Murray, G. K., Byrne, E. M., Sidorenko, J., Vischer, P. M., Wray, N. R., et al. (2021). GWAS of peptic ulcer disease implicates Helicobacter pylori infection, other gastrointestinal disorders and depression. Nat. Commun. 12 (1), 1146. doi:10.1038/s41467-021-21280-7

Zhang, F., Cao, H., and Baranova, A. (2022). Genetic variation mediating neurotrophism’s influence on cardiovascular diseases. J. Psychopathol. Clin. Sci. 131 (3), 278–286. doi:10.1037/abn0000744

Zhang, F., Cao, H., and Baranova, A. (2021). Shared genetic liability and causal associations between major depressive disorder and cardiovascular diseases. Front. Cardiovasc. Med. 8, 735136. doi:10.3389/fcvm.2021.735136

Zhou, Y., Liang, Z.-S., Jin, Y., Ding, J., Huang, T., Moore, J. H., et al. (2021). Shared genetic architecture and causal relationship between asthma and cardiovascular diseases: A large-scale cross-trait analysis. Front. Genet. 12, 775591. doi:10.3389/fgene.2021.775591